Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase
Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)
DOI: 10.1128/aac.01960-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Xiaowen Liang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenzhen University Medical School, Shenzhen Unversity, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Aminopterin, Tetrahydrofolate Dehydrogenase, Antiviral Agents, Adenoviruses, Human. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human adenovirus (HAdV) is one of the most infectious pathogens that can cause diseases affecting multiple organ systems, posing a significant threat to public health. Currently, there are no specific antiviral therapies available for HAdV infection. In this study, three folate antagonists aminopterin (AMT), pralatrexate (PDX), and methotrexate (MTX) with potent antiviral activity against HAdV infection have been identified through a drug repurposing screening strategy. The three drugs showed broad and potent antiviral efficiency against multiple clinically prevalent HAdV serotypes, including HAdV-B3, HAdV-B7, HAdV-B55, HAdV-C2, and HAdV-C5 with half-maximal effective concentration (EC 50 ) values ranging from 0.31 to 79.74 nM, and PDX further showed similar antiviral efficiency against HAdV-B55 in a 3D lung organoid model (EC 50 = 0.51 nM). Mechanistic studies revealed that PDX achieved its antiviral activity through suppression of dihydrofolate reductase (DHFR). These findings support the potential of folate antagonists as repurposed therapeutic agents against HAdV infection and provide a rationale for the development of host-directed antiviral strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shenzhen University Medical School, Shenzhen Unversity, Shenzhen, Guangdong, China.
- Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
- National Clinical Research Center for Infectious Diseases, Shenzhen, China.
- Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Department of Infectious Disease, The People's Hospital of Longhua, Shenzhen, China.
ORCID-Profile: Yong Feng, Weihua Wu, Chunmei Jiang, Liuqing Yang, Fuxiang Wang, Yang Yang
Zitieren
APA
Liang, X., Feng, Y., Xu, C., Wang, Y., Yang, W., Kuang, J., Luo, Y., Wu, W., Chang, F., Fu, L., Liu, Y., Jiang, C., Yang, L., Wang, F., & Yang, Y. (2026). Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.01960-25
Vancouver
Liang X, Feng Y, Xu C, Wang Y, Yang W, Kuang J, et al. Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.01960-25
BibTeX
@article{Liang2026,
author = {Liang, Xiaowen and Feng, Yong and Xu, Chang and Wang, Yuelin and Yang, Wei and Kuang, Jiahua and Luo, Yanling and Wu, Weihua and Chang, Fangfang and Fu, Lifeng and Liu, Yingxia and Jiang, Chunmei and Yang, Liuqing and Wang, Fuxiang and Yang, Yang},
title = {Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {7},
doi = {10.1128/aac.01960-25}
}
EUVIMED